Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Full description
Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For inclusion in the study, patients should fulfill the following criteria:
Exclusion criteria
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Primary purpose
Allocation
Interventional model
Masking
800 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
AstraZeneca Clinical Study Information Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal